E10.22

Type 1 diabetes mellitus with diabetic chronic kidney disease

## Overview of Type 1 Diabetes Mellitus with Diabetic Chronic Kidney Disease (E10.22) Type 1 diabetes mellitus (T1DM) with diabetic chronic kidney disease (DKD), coded as E10.22, represents a severe and common microvascular complication of T1DM, leading to progressive renal impairment. This condition is characterized by the presence of persistent albuminuria and/or a progressive decline in the glomerular filtration rate (GFR) in individuals with T1DM, without evidence of other primary causes of kidney disease. ### Pathophysiology Type 1 diabetes mellitus is an autoimmune disease resulting in the destruction of pancreatic beta cells, leading to absolute insulin deficiency. The primary driver of DKD in T1DM is chronic hyperglycemia. Sustained elevated blood glucose levels initiate a cascade of biochemical and hemodynamic changes within the kidney. Key mechanisms include the activation of various metabolic pathways: 1. **Advanced Glycation End Products (AGEs)**: Hyperglycemia leads to the non-enzymatic glycation of proteins and lipids, forming AGEs. These compounds accumulate in the kidney, particularly in the glomerular basement membrane and mesangium, contributing to structural damage, increased oxidative stress, and inflammation. 2. **Protein Kinase C (PKC) Activation**: Elevated glucose levels activate PKC isoforms, which in turn modulate various cellular functions, contributing to increased permeability, altered blood flow, and extracellular matrix expansion. 3. **Oxidative Stress**: Hyperglycemia generates reactive oxygen species, leading to oxidative stress, which damages renal cells and promotes inflammation and fibrosis. 4. **Renin-Angiotensin-Aldosterone System (RAAS) Activation**: T1DM can lead to intrarenal RAAS activation, contributing to glomerular hyperfiltration, hypertension, and profibrotic effects. These molecular changes result in characteristic histopathological alterations in the glomeruli and tubulointerstitium. Initially, there is glomerular hyperfiltration, followed by thickening of the glomerular basement membrane, expansion of the mesangium (diffuse and nodular glomerulosclerosis, or Kimmelstiel-Wilson lesions), loss of podocytes, and eventual glomerulosclerosis. Concurrently, tubulointerstitial fibrosis develops, contributing significantly to the decline in renal function. The disease typically progresses through stages, starting with microalbuminuria (urinary albumin excretion 30-300 mg/24 hours or albumin-to-creatinine ratio [ACR] 30-300 mg/g) to macroalbuminuria (>300 mg/24 hours or ACR >300 mg/g) and eventually to end-stage renal disease (ESRD). ### Clinical Presentation In its early stages, DKD is largely asymptomatic. The earliest clinical manifestation is persistent microalbuminuria. As kidney function declines, patients may develop hypertension, often difficult to control, and peripheral edema. In more advanced stages, symptoms become more pronounced due to the accumulation of metabolic waste products (uremia). These can include fatigue, anorexia, nausea, vomiting, metallic taste in the mouth, muscle cramps, restless legs syndrome, pruritus, and cognitive impairment. Anemia, hyperkalemia, metabolic acidosis, and bone disease (renal osteodystrophy) are common complications of advanced CKD. Diabetic retinopathy often coexists with DKD, and its presence can strongly suggest a diabetic etiology for kidney disease. ### Diagnostic Criteria The diagnosis of T1DM with DKD typically involves: 1. **Diagnosis of T1DM**: Confirmation of Type 1 diabetes, usually based on clinical presentation, autoantibody testing (e.g., GAD65, ICA, IA-2, ZnT8), and C-peptide levels indicating severe insulin deficiency. 2. **Assessment of Kidney Damage**: Persistent albuminuria, defined as an ACR ≥ 30 mg/g (or 3 mg/mmol) in at least two out of three urine samples collected over a 3- to 6-month period. Additionally, a progressive decline in estimated GFR (eGFR) below 60 mL/min/1.73 m² is indicative of CKD. 3. **Exclusion of Other Kidney Diseases**: It is crucial to rule out other primary causes of kidney disease, especially in cases with atypical presentation (e.g., sudden onset of proteinuria, rapid decline in GFR, absence of retinopathy, active urinary sediment). Renal biopsy may be considered in such atypical scenarios to differentiate DKD from other glomerular diseases. ### Standard of Care The management of T1DM with DKD is multifaceted, focusing on intensive glycemic control, blood pressure management, and renoprotective therapies: 1. **Glycemic Control**: Intensive insulin therapy aiming for an HbA1c target of less than 7% (individualized based on age, duration of diabetes, and comorbidities) is crucial to prevent the initiation and progression of DKD. Continuous glucose monitoring can aid in achieving optimal control while minimizing hypoglycemia. 2. **Blood Pressure Management**: Strict blood pressure control is paramount, typically targeting less than 130/80 mmHg. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are first-line agents due to their renoprotective effects, even in normotensive patients with albuminuria. Combination therapy with other antihypertensives may be necessary. 3. **Renoprotective Agents**: Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated significant cardiorenal protective benefits beyond glycemic control in patients with T1DM and DKD, and are increasingly recommended. 4. **Lipid Management**: Aggressive management of dyslipidemia with statins is recommended to reduce cardiovascular risk, which is significantly elevated in patients with DKD. 5. **Dietary and Lifestyle Modifications**: A low-sodium diet, moderate protein restriction (typically 0.8 g/kg/day in later stages of CKD), regular physical activity, and smoking cessation are vital. 6. **Avoidance of Nephrotoxic Agents**: Careful use of NSAIDs, contrast agents, and other nephrotoxic drugs is essential. 7. **Management of Complications**: Anemia, hyperkalemia, and metabolic acidosis should be managed appropriately. 8. **Renal Replacement Therapy**: For patients progressing to ESRD, options include dialysis (hemodialysis or peritoneal dialysis) or kidney transplantation, often combined with pancreas transplantation for T1DM patients.

Clinical Symptoms

  • Persistent microalbuminuria (early sign, asymptomatic)
  • Macroalbuminuria
  • Progressive decline in estimated GFR
  • Hypertension (often difficult to control)
  • Peripheral edema (swelling in legs, ankles, feet)
  • Generalized fatigue and weakness
  • Loss of appetite (anorexia)
  • Nausea and vomiting
  • Metallic taste in mouth
  • Muscle cramps
  • Restless legs syndrome
  • Pruritus (itching)
  • Cognitive impairment (difficulty concentrating, confusion)
  • Shortness of breath (due to fluid overload or anemia)
  • Nocturia (frequent urination at night)
  • Foamy urine (due to proteinuria)
  • Anemia (pallor, dizziness)
  • Hyperkalemia (palpitations, muscle weakness)
  • Uremic frost (very late stage, rare)

Common Causes

  • Type 1 Diabetes Mellitus (primary underlying cause)
  • Chronic hyperglycemia (sustained elevated blood glucose levels)
  • Uncontrolled hypertension
  • Long duration of diabetes
  • Genetic predisposition and familial history of DKD
  • Smoking
  • Dyslipidemia (abnormal lipid levels)
  • Obesity
  • High dietary protein intake (can exacerbate progression)
  • Recurrent urinary tract infections
  • Exposure to nephrotoxic medications (e.g., NSAIDs, certain antibiotics, contrast agents)

Documentation & Coding Tips

Clearly establish the causal link between Type 1 Diabetes Mellitus and Chronic Kidney Disease. Explicitly state 'diabetic nephropathy' or 'CKD due to diabetes' to support E10.22.

Example: Patient is a 45-year-old male with long-standing Type 1 DM presenting for routine follow-up. HbA1c 8.2%. Renal function has progressively declined; eGFR is 38 mL/min/1.73m^2 (Stage G3b), with persistent albuminuria (UACR 450 mg/g). Diagnosis of diabetic nephropathy secondary to T1DM confirmed. Patient continues on insulin glargine 30 units qhs and insulin aspart pre-meals. Referred to nephrology for management of advanced CKD. This documentation links T1DM directly to CKD, supporting E10.22, and specifies CKD stage (N18.3B), providing higher risk adjustment. Insulin use is also noted, impacting HCC.

Billing Focus: Explicitly state the 'due to' relationship (diabetic nephropathy). Document current insulin therapy and kidney disease stage (e.g., Stage G3b, N18.3B) for maximum specificity.

Document the current stage of Chronic Kidney Disease according to KDIGO guidelines (eGFR and albuminuria) to ensure accurate coding and severity assessment.

Example: Patient with T1DM and known CKD. Current eGFR 25 mL/min/1.73m^2 (CKD Stage G4) and UACR 650 mg/g (Albuminuria A3). Patient reports increased fatigue and occasional peripheral edema. Continue strict blood glucose control with insulin pump (daily total 45 units). Initiated low-protein diet education. This allows for coding E10.22 and N18.4 (CKD Stage 4), capturing a higher level of severity and resource utilization. Insulin pump management supports higher E/M coding.

Billing Focus: Detailed staging of CKD (e.g., G3a, G3b, G4, G5) using eGFR and albuminuria metrics. These specific stages have distinct ICD-10 codes (N18.30-N18.5) that should be co-reported.

Describe the current management plan for both Type 1 DM (e.g., insulin regimen, glucose monitoring) and CKD (e.g., medications, dietary restrictions, specialist referrals).

Example: 48-year-old Type 1 DM patient with diabetic CKD, Stage 3a. Managed on basal-bolus insulin regimen (Tresiba 20 units daily, Novolog 5 units with meals). Home glucose monitoring shows readings 120-180 mg/dL. Renal diet counseling provided. Lisinopril 10 mg daily for blood pressure and renal protection. Nephrology follow-up every 6 months. This detail supports the chronic nature of E10.22 and the active management, justifying higher E/M levels. The specific medications contribute to risk adjustment.

Billing Focus: Specific insulin types and dosages, frequency of glucose monitoring, diet education, and all prescribed medications (especially those targeting kidney protection like ACE inhibitors/ARBs). Specialist referrals (nephrology, endocrinology) indicate ongoing care coordination.

Document associated complications of diabetes, even if not directly kidney-related, to paint a complete clinical picture and capture all relevant HCCs.

Example: Patient with T1DM and diabetic CKD G3b. Also noted to have diabetic retinopathy (mild, non-proliferative, stable, H35.033) and peripheral neuropathy with paresthesias in bilateral feet (G63.0*). Foot exam reveals intact sensation with vibratory loss in toes. Continues strict glycemic control and nephroprotective measures. Documenting associated complications such as retinopathy or neuropathy (even if not coded with E10.22 as primary) helps paint a comprehensive picture of the patient's diabetic burden, contributing to multiple HCCs and a more accurate risk score.

Billing Focus: Specific mention of other microvascular (retinopathy, neuropathy) or macrovascular (CAD, PVD) diabetic complications, including laterality and severity when applicable.

Regularly assess and document the impact of CKD on other body systems and the patient's overall functional status.

Example: Patient with long-standing T1DM and diabetic CKD G4 presents with worsening anemia (Hb 9.8 g/dL), managed with darbepoetin alpha 40 mcg SC weekly (D63.1*). Also experiencing fatigue and decreased exercise tolerance related to renal insufficiency. Cardiac exam shows no S3/S4, lungs clear. This demonstrates the systemic impact of CKD, supporting the severity of E10.22 and allowing for additional coding of complications like renal anemia. The active management of anemia with a specific medication further supports complexity.

Billing Focus: Documenting complications directly attributable to CKD (e.g., anemia of CKD, secondary hyperparathyroidism, fluid overload).

Relevant CPT Codes

Related Diagnoses

Hierarchy